Sodium-glucose co-transporter-2 (SGLT-2) inhibitors represent a major step in the management of chronic kidney disease (CKD), with evidence from several large randomised clinical trials and collaborative meta-analyses indicating that this medication class reduces progression of kidney disease and kidney failure in a broad range of people with CKD irrespective of diabetes (DM) status, level of kidney function, or primary kidney diagnosis [1–4]. Here, SLC5A2 is linked to chronic kidney disease.